“…It acts by stimulating both innate and cell-mediated immunity pathways, activates antigen-presenting cells through toll-like receptor 7, and stimulates cytotoxic T-cells, Langerhans cells, and natural killer cells to produce interferon-gamma and other cytokines, which cause apoptosis (5). US Food and Drug Administration (FDA) approved IMQ for anogenital warts in 1997, and for superficial basal cell carcinoma (BCC) and AK in 2004 (6,7). Other clinical indications are lentigo maligna, extramammary Paget's disease, Bowen's disease, xeroderma pigmentosum, and molluscum contagiosum (8).…”